Clinical trials: Cancer, Advanced Solid Tumors
EGFR Exon 20 Mutation, ERBB2 Gene Mutation
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent).
- Conditions
- EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03066206
- Testing
- Poziotinib
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor Malignancies
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies
The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044.
- Trial name
- NCT06649708
- Testing
- HX044
- Where
- 3 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Advanced Solid Tumors
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Alkaline phosphatase (ALP) is a membrane-bound glycoprotein that catalyzes the hydrolysis of phosphates at alkaline pH values. As one of the earliest discovered oncofetal antigens, ALP has emerged as a significant biomarker for…
- Trial name
- NCT06556108
- Testing
- ALPP CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xinqiao Hospital of Chongqing
Advanced Solid Tumor
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
The purpose of this study is to evaluate the Effect of Omeprazole on the Pharmacokinetics of Fluzoparib in Healthy male Adults.
- Trial name
- NCT04108676
- Testing
- Fluzoparib, Omeprazole
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Ribociclib (LEE011) Rollover Study for Continued Access
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011)…
- Trial name
- NCT02934568
- Testing
- LEE011
- Where
- 13 sites in United States, France and 4 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose…
- Trial name
- NCT05277168
- Testing
- SHR-A1904
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1.
- Trial name
- NIMBLe (NCT03461952)
- Testing
- Nivolumab, Ipilimumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 4 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus expressing interferon beta in treating patients with liver cancer or solid tumors with lesions that have spread to other parts of…
- Trial name
- NCT01628640
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Neoplasms
Dose-escalation Study of Lupartumab Amadotin (BAY1129980)
The purpose of this study is to evaluate: The side effects of BAY1129980 when given every 21 days different dose levels. Determine the dose level of BAY1129980 that should be tested in future clinical research studies.
- Trial name
- NCT02134197
- Testing
- Lupartumab Amadotin (BAY1129980)
- Where
- 15 sites in United States
- Volunteers
- 69 people
- Sponsor
- Bayer
Unspecified Adult Solid Tumor, Protocol Specific
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005078
- Testing
- carboplatin, paclitaxel, tirapazamine
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
This phase I trial tests the safety, side effects, and best dose of MTI-301 in treating patients with solid cancers that have spread from where they first started (primary site) to other places in the body (metastatic) or that…
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT06911008
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Solid Tumours
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation…
- Trial name
- NCT01928940
- Testing
- dabrafenib, trametinib
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Solid Tumor
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to evaluate the safety, tolerability, and PK of IGM-7354 in participants with relapsed and/or refractory tumors.
- Trial name
- NCT05702424
- Testing
- IGM-7354
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- IGM Biosciences, Inc.
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Biliary Tract Cancer
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT05784688
- Testing
- TU2218 + KEYTRUDA® (Pembrolizumab)
- Where
- 11 sites in United States, South Korea
- Volunteers
- 140 people
- Sponsor
- TiumBio Co., Ltd.
Cancer, Neoplasms
Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors
Human epidermal growth factor receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis.
- Trial name
- NCT02345174
- Testing
- GSK2849330, 89Zr-GSK2849330
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
PD-1 Antibody, CAR-T Cells
PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed…
- Conditions
- PD-1 Antibody, CAR-T Cells, Advanced Malignancies
- Trial name
- NCT02873390
- Testing
- HerinCAR-PD1 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ningbo Cancer Hospital
Solid Tumor, Adult Lymphoma
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily.
- Trial name
- NCT05358379
- Testing
- CYC140
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 330 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Solid Tumors
Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors
This is an open-label, sequential dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of DS-8895a in Japanese subjects with advanced solid tumors.
- Trial name
- NCT02004717
- Testing
- DS-8895a
- Where
- 2 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.